Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Mass Balance of Belumosudil in Healthy Men
NCT03907540Phase 1Completed
- Sponsor
- Kadmon
- Start
- Apr 2019
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of belumosudil in autoimmune diseases and fibrosis, sponsored by Kadmon. Primary endpoints: Absolute Bioavailability of Belumosudil 200 mg Tablet, Mass Balance Recovery Following 200 mg Oral Dose of [14C]-KD025 Capsule and 2 more. Started Apr 2019; status: completed.
02
Drugs
belumosudil
03
Conditions
autoimmune diseasesfibrosis
Beyond the preview
Go deeper on NCT03907540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03907540.